06:00 AM EST, 11/12/2026 (MT Newswires) -- Berenberg raised its price target for Sartorius (SRT.F) after the German life science equipment and technology supplier posted "very strong" third-quarter results with accelerating underlying growth. "Critically for us, organic growth (excluding Mattek) rose each quarter, from 7.0% in Q1 to 7.4% in Q2 and 9.0% in Q3. Further adjusting for tariff surcharges (a tailwind in H1 and a headwind in Q3), we estimate underlying growth accelerated from c6.5% in H1 to c9.4% in Q3. Most of this came from exceptionally strong Lab Products & Services (LPS) performance, which benefited from some pull-forward but appears largely underlying, while Bioprocess Solutions (BPS), importantly, also accelerated," according to a Thursday note. Against this backdrop, the research firm lifted its price target to 340 euros from 280 euros and reiterated its buy rating on the stock, to account for higher operating estimates and a sector-wide re-rating. While sales and EBIT forecasts for full-year 2026 through 2028 were revised upward, Berenberg's adjusted EPS estimates for the same period fell by up to 3% as operational upgrades were offset by the proper deduction of minority interests' share of adjustments.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.